- Home
- core 10 scoring
- Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic
4.5 (576) · $ 19.99 · In stock
/cms/asset/b6d321b3-1847-46ce-8
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
View of Ciltacabtagene Autoleucel (Carvykti)
Emre Yucel on LinkedIn: How is it possible that such dangerous copycat eyedrops made way to the…
CONSORT diagram AE adverse event, PBSC peripheral blood stem cell
Cancers, Free Full-Text
Health-related quality of life change over time. Estimated change in
Health-related quality of life in the ENDEAVOR study: carfilzomib- dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Kaplan–Meier curves of OS from transplant of patients with myeloma who
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
JPatientRepOutcomes (@JPRO_ISOQOL) / X
Change in FACT‐BMT score between baseline and 1‐year post‐transplant.
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
